WO2019050362A3 - 인간 dlk1에 대한 항체 및 이의 용도 - Google Patents
인간 dlk1에 대한 항체 및 이의 용도Info
- Publication number
- WO2019050362A3 WO2019050362A3 PCT/KR2018/010559 KR2018010559W WO2019050362A3 WO 2019050362 A3 WO2019050362 A3 WO 2019050362A3 KR 2018010559 W KR2018010559 W KR 2018010559W WO 2019050362 A3 WO2019050362 A3 WO 2019050362A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- antibody against
- antibody
- against human
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
Abstract
본 발명은 DLK1(delta-like 1 homolog (Drosophila))에 대한 항체 또는 이의 항원 결합 단편, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 그의 항원 결합 단편의 제조방법, 이를 포함하는 항체-약물 접합체(Antibody drug conjugate: ADC), 암 치료용 약학 조성물, 암 진단용 조성물, 이를 포함하는 키메라 항원 수용체(Chimeric antigen receptor: CAR) 및 T 세포 관여자(T-cell engager)에 관한 것이다.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020514200A JP7027530B2 (ja) | 2017-09-08 | 2018-09-10 | ヒトdlk1に対する抗体及びその用途 |
EP18853205.5A EP3683236A4 (en) | 2017-09-08 | 2018-09-10 | ANTIBODIES TO HUMANES DLK1 AND ITS USES |
CN201880068881.7A CN111278860B (zh) | 2017-09-08 | 2018-09-10 | 抗人dlk1的抗体及其用途 |
US16/644,764 US11306141B2 (en) | 2017-09-08 | 2018-09-10 | Antibody against human DLK1 and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0115263 | 2017-09-08 | ||
KR20170115263 | 2017-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019050362A2 WO2019050362A2 (ko) | 2019-03-14 |
WO2019050362A3 true WO2019050362A3 (ko) | 2019-05-02 |
Family
ID=65634340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/010559 WO2019050362A2 (ko) | 2017-09-08 | 2018-09-10 | 인간 dlk1에 대한 항체 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11306141B2 (ko) |
EP (1) | EP3683236A4 (ko) |
JP (1) | JP7027530B2 (ko) |
KR (1) | KR102125032B1 (ko) |
CN (1) | CN111278860B (ko) |
WO (1) | WO2019050362A2 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
CN117244076A (zh) | 2015-11-25 | 2023-12-19 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
US11167040B2 (en) | 2015-11-25 | 2021-11-09 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
KR101938800B1 (ko) | 2017-03-29 | 2019-04-10 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
TW202000239A (zh) | 2018-05-09 | 2020-01-01 | 韓商樂高化學生物科學股份有限公司 | 與抗cd19抗體藥物結合物相關之組合物及方法 |
WO2020180121A1 (ko) * | 2019-03-06 | 2020-09-10 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
KR102503143B1 (ko) * | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090088893A (ko) * | 2006-11-10 | 2009-08-20 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체 |
KR100982170B1 (ko) * | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
KR20120113175A (ko) * | 2011-04-04 | 2012-10-12 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
KR20170051579A (ko) * | 2015-10-29 | 2017-05-12 | 주식회사 와이바이오로직스 | Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1988000649A1 (fr) | 1986-07-16 | 1988-01-28 | Systems Water Motor S.N.C. | Dispositif d'admission d'eau pour moteurs a combustion interne |
DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Lab Inc | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
AU605291B2 (en) | 1987-03-20 | 1991-01-10 | Micromet Ag | Process for the purification of recombinant polypeptides |
AU601273B2 (en) | 1987-03-20 | 1990-09-06 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US20050221392A1 (en) | 2002-03-21 | 2005-10-06 | Charlotte Harken Jensen | Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1 |
JP5615169B2 (ja) * | 2008-03-17 | 2014-10-29 | 株式会社リブテック | invivoで抗腫瘍活性を有する抗ヒトDlk−1抗体 |
WO2012138102A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
KR101995751B1 (ko) | 2012-01-05 | 2019-07-03 | 주식회사 와이바이오로직스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
LT2905335T (lt) | 2012-10-03 | 2018-04-10 | Chiome Bioscience Inc. | Antikūnas prieš žmogaus dlk-1, pasižymintis priešnavikiniu aktyvumu in vivo sąlygomis |
KR102503143B1 (ko) * | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
-
2018
- 2018-09-10 WO PCT/KR2018/010559 patent/WO2019050362A2/ko unknown
- 2018-09-10 US US16/644,764 patent/US11306141B2/en active Active
- 2018-09-10 CN CN201880068881.7A patent/CN111278860B/zh active Active
- 2018-09-10 JP JP2020514200A patent/JP7027530B2/ja active Active
- 2018-09-10 EP EP18853205.5A patent/EP3683236A4/en active Pending
- 2018-09-10 KR KR1020180107639A patent/KR102125032B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090088893A (ko) * | 2006-11-10 | 2009-08-20 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체 |
KR100982170B1 (ko) * | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
KR20120113175A (ko) * | 2011-04-04 | 2012-10-12 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
KR20170051579A (ko) * | 2015-10-29 | 2017-05-12 | 주식회사 와이바이오로직스 | Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물 |
Non-Patent Citations (1)
Title |
---|
BEGUM, A. ET AL.: "DLK1, Delta-like 1 Homolog (Drosophila), Regulates Tumor Ceil Differentiation in Vivo", CANCER LETTER, vol. 318, no. 1, 1 May 2012 (2012-05-01), pages 26 - 33, XP028897260, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2011.11.032 * |
Also Published As
Publication number | Publication date |
---|---|
US20210214432A1 (en) | 2021-07-15 |
US11306141B2 (en) | 2022-04-19 |
JP7027530B2 (ja) | 2022-03-01 |
KR20190028350A (ko) | 2019-03-18 |
JP2021502797A (ja) | 2021-02-04 |
EP3683236A2 (en) | 2020-07-22 |
WO2019050362A2 (ko) | 2019-03-14 |
CN111278860B (zh) | 2024-03-29 |
KR102125032B1 (ko) | 2020-06-19 |
CN111278860A (zh) | 2020-06-12 |
EP3683236A4 (en) | 2021-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019050362A3 (ko) | 인간 dlk1에 대한 항체 및 이의 용도 | |
MX2023007400A (es) | Moleculas de union a bcma y metodos de uso de las mismas. | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
PE20190976A1 (es) | Anticuerpos de union a cd3 | |
WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
MX2021004588A (es) | Anticuerpo anti-cldn18.2 y sus usos. | |
NZ601617A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
PH12017500890A1 (en) | Antibody drug conjugates | |
UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
MX2019009119A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MX2017005642A (es) | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. | |
MX2018012473A (es) | Agentes que reconocen el epitopo de clever-1 y usos de los mismos. | |
PH12019501050A1 (en) | ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF | |
CR20220049A (es) | Moléculas de unión a claudina-6 y usos de las mismas | |
WO2019078699A3 (ko) | 항-vista 항체 및 이의 용도 | |
MX2022007706A (es) | Anticuerpos utiles en diagnosis de cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18853205 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2020514200 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018853205 Country of ref document: EP Effective date: 20200408 |